Press Releases

DAY HI:
DAY LOW:
VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Mar 02, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 2, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented results from Cohort 3 and initial twice daily (BID) dosing safety and efficacy data for poziotinib from Cohort 5
Feb 26, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 26, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on interim safety evaluation of same-day dosing of ROLONTIS ® (eflapegrastim) in patients
Feb 23, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 23, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced two presentations, one oral and one eposter, at the upcoming European Society for Medical Oncology Targeted
Feb 04, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 4, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2021 Oncology Day.
Jan 22, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 22, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced an oral presentation on updated efficacy, safety, and dosing management of poziotinib from Cohorts 1 and 2 of
Jan 05, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Jan. 5, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will provide an overview of the company's business strategy and development-stage programs at
Dec 22, 2020
FDA agrees to the submission of an NDA for poziotinib for non-small cell lung cancer (NSCLC) in previously treated patients with HER2 exon 20 insertion mutations, NDA submission planned for 2021 Cohort 3 of the ZENITH20 clinical trial, which enrolled first-line NSCLC patients with EGFR exon 20
Dec 14, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 14, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Nora Brennan to its Board of Directors. Ms. Brennan fills a vacancy left by Ms.
Dec 04, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 4, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that three posters highlighting its drug development pipeline would be presented at the upcoming San Antonio
Nov 09, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 9, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at
Nov 04, 2020
FDA deferred action on the BLA for ROLONTIS ® (eflapegrastim)   due to inability to conduct inspection of the manufacturing facility citing COVID-19 related travel restrictions Pre-NDA meeting with FDA is scheduled for poziotinib in NSCLC HER2 exon-20 insertion mutations in previously treated
Oct 28, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 28, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2020 financial results and provide a corporate
Oct 26, 2020
Agency cites inability to conduct inspection of the drug substance manufacturing facility due to COVID-19 related travel restrictions HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 26, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology
Sep 18, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 18, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented additional results from its pivotal Phase 2 clinical trial, ZENITH20, evaluating poziotinib in previously
Sep 14, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 14, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a presentation of the results for Cohort 2 from its Phase 2 clinical trial, ZENITH20, evaluating poziotinib in
Sep 08, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 8, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at
Aug 10, 2020
Recently announced positive topline results in HER2 exon 20 insertion mutations from Cohort 2 of the poziotinib ZENITH20 trial Company is in process of requesting a pre-NDA meeting with the FDA seeking an indication for second-line NSCLC patients with HER2 exon 20 insertion mutations BLA for
Aug 05, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 5, 2020-- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the underwriters of its previously announced public offering of common
Aug 03, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 3, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2020 financial results and provide a corporate
Jul 30, 2020
HENDERSON, Nev. --(BUSINESS WIRE)--Jul. 30, 2020-- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the pricing of an underwritten public offering of 21,666,667 shares of its
Displaying 1 - 20 of 831